Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | APR-246 and azacitidine in TP53m MDS and AML

Thomas Cluzeau • 7 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine Eprenetapopt

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the results of a Groupe Francophone Des Myélodysplasies (GFM) phase II study of azacitidine combined with APR-246 in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Thomas Cluzeau

The potential association of plasma venetoclax level with treatment efficacy in first-line AML
2:08
The potential association of plasma venetoclax level with treatment efficacy in first-line AML
Thomas Cluzeau • 8 Dec 2025
Crenolanib plus salvage chemotherapy in FLT3-mutant R/R AML: results from a randomized trial
2:44
Crenolanib plus salvage chemotherapy in FLT3-mutant R/R AML: results from a randomized trial
Thomas Cluzeau • 8 Dec 2025
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
21:29
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
Thomas Cluzeau • 19 Sep 2025
Novel targets, treatments, and combinations in AML
Novel targets, treatments, and combinations in AML
Thomas Cluzeau • 29 Sep 2022

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Thomas Cluzeau • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Thomas Cluzeau • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Thomas Cluzeau • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Thomas Cluzeau • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals